Cipla Limited
CIPLA
Classifica tra le azioni
#1816
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Prezzo delle azioni
$14.63
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$11.82B
Variazione (1 giorno)
0.39%
Variazione (1 anno)
-18.37%
Paese
IN
Scambia Cipla Limited (CIPLA)
Categoria
Healthcare
EPS per Cipla Limited (CIPLA)
EPS al June 2026 TTM: $0.46
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Cipla Limited, l’EPS attuale della società (TTM) è $0.46. Alla fine del 2024, la società aveva un EPS di $0.61 un aumento rispetto a rispetto a quello del 2023, che era di $0.42.
Storico EPS per Cipla Limited da 2004 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $0.46 | -39.39% |
| 2025 | $0.76 | 24.70% |
| 2024 | $0.61 | 44.90% |
| 2023 | $0.42 | 2.80% |
| 2022 | $0.41 | 0.88% |
| 2021 | $0.41 | 59.95% |
| 2020 | $0.25 | -6.77% |
| 2019 | $0.27 | 1.49% |
| 2018 | $0.27 | 39.41% |
| 2017 | $0.19 | -24.42% |
| 2016 | $0.26 | 8.40% |
| 2015 | $0.24 | -18.30% |
| 2014 | $0.29 | -18.53% |
| 2013 | $0.35 | 26.01% |
| 2012 | $0.28 | 1.66% |
| 2011 | $0.28 | -9.38% |
| 2010 | $0.31 | 56.09% |
| 2009 | $0.20 | -13.31% |
| 2008 | $0.23 | 13.49% |
| 2007 | $0.20 | 9.18% |
| 2006 | $0.18 | 45.52% |
| 2005 | $0.13 | 37.67% |
| 2004 | $0.09 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | 20.78% |
IN
|
